About
Qubit Pharmaceuticals FeNNix is a cutting-edge computational drug discovery platform built on three decades of quantum chemistry research. At its core is the ATLAS platform, the world's first quantum-enabled AI foundation model that unifies Physics, AI, and Quantum Computing for superior molecular modeling and simulation. FeNNix leverages proprietary first-principles synthetic data and applies transfer learning across DFT, QMC, sCI, and FCI methods, enabling fast and cost-effective data generation with unmatched chemical accuracy. The platform delivers over 1,000 nanoseconds of molecular dynamics simulation per day using polarizable force fields, supported by more than 50 PetaFLOPS of dedicated AI computing and hybrid HPC-QC infrastructure ready for 30+ qubit computations. This allows researchers to model and optimize drug candidates against targets previously considered too complex, dramatically de-risking and accelerating the drug discovery pipeline. FeNNix supports a broad pipeline including oncology (KAT6A, RAS/RAF, USP7), inflammation (IL4R), and antiviral programs, with 16+ additional programs under evaluation. The platform also extends beyond pharma into broader chemical industries, enabling applications wherever quantum-level accuracy in molecular design is required. It is designed for biotech and pharmaceutical enterprises seeking to move from traditional drug hunting toward a more systematic, AI-driven drug farming paradigm.
Key Features
- ATLAS Quantum-AI Platform: The world's first quantum-enabled foundation model unifying Physics, AI, and Quantum Computing for superior molecular modeling, simulation, and molecule generation.
- Ultra-High-Speed Molecular Dynamics: Delivers 1,000+ nanoseconds of MD simulation per day using polarizable force fields, enabling detailed and accurate molecular behavior studies at scale.
- Proprietary First-Principles Data Generation: Generates synthetic training data from quantum chemistry (DFT, QMC, sCI, FCI) and applies transfer learning to achieve chemical accuracy efficiently and cost-effectively.
- Hybrid HPC-QC Infrastructure: Supports hybrid high-performance computing and quantum computing workflows with readiness for 30+ qubit computations, future-proofing computational drug discovery pipelines.
- Broad Drug Pipeline Coverage: Covers 16+ drug discovery programs across oncology, inflammation, and antiviral targets, including previously undruggable targets like RAS/RAF, KAT6A, IL4R, and GPCRs.
Use Cases
- Pharmaceutical companies modeling complex protein targets (e.g., RAS/RAF, GPCRs) previously considered undruggable to identify novel drug candidates.
- Biotech firms accelerating hit-to-lead and lead optimization workflows by replacing costly wet-lab experiments with high-fidelity quantum-AI simulation.
- Research institutions and academic labs partnering with Qubit to leverage quantum chemistry datasets and transfer learning for novel molecular property prediction.
- Oncology and immunology drug programs requiring precise free energy calculations and molecular dynamics to predict binding affinities and selectivity profiles.
- Chemical industry R&D teams using quantum-accurate molecular modeling to design novel materials, catalysts, or agrochemical compounds at scale.
Pros
- Unmatched Molecular Accuracy: Achieves the highest accuracy in solving Schrödinger's equation commercially, enabling reliable modeling of highly complex drug targets.
- Dramatic Reduction in Discovery Time and Cost: Cuts drug candidate selection time in half and reduces experimental validation requirements by at least tenfold, providing significant ROI for pharma partners.
- Cross-Industry Applicability: Extends beyond pharma into broader chemical industries, making it versatile for any domain requiring quantum-level molecular accuracy.
- Deep Scientific Pedigree: Founded by world-leading quantum lab heads with 30+ years of research, backed by a 60+ person expert team across deep tech and pharma.
Cons
- Enterprise-Only Access: The platform is designed for large biotech and pharmaceutical organizations, making it inaccessible and cost-prohibitive for small research teams or academic use without partnership.
- Steep Learning Curve: Requires deep expertise in computational chemistry and quantum physics to fully leverage the platform's capabilities, limiting adoption to highly specialized teams.
- Limited Public Pricing Transparency: Pricing and access details are not publicly disclosed, requiring direct engagement with the company for evaluation, which can slow procurement decisions.
Frequently Asked Questions
What is the FeNNix platform?
FeNNix is Qubit Pharmaceuticals' AI and quantum physics-based drug discovery platform, built on the ATLAS foundation model. It combines quantum mechanics, AI, and HPC to deliver high-precision molecular simulation and molecule generation for drug discovery.
How does FeNNix differ from traditional computational drug discovery tools?
Unlike conventional tools, FeNNix achieves quantum-level chemical accuracy by solving Schrödinger's equation with unprecedented precision. It integrates quantum computing readiness, polarizable force fields, and AI-driven chemical space exploration, far surpassing classical simulation methods.
What therapeutic areas does Qubit Pharmaceuticals focus on?
Qubit focuses primarily on oncology, inflammation, and pandemic/antiviral response, with active programs targeting KAT6A, IL4R, RAS/RAF, TREX1, USP7, and multiple RNA and GPCR platforms, plus 16+ additional programs under evaluation.
Can FeNNix be used outside of pharmaceuticals?
Yes. The platform's ability to learn underlying chemistry and physics rules makes it applicable across broader chemical industries, including materials science and agrochemicals, wherever quantum-accurate molecular design is needed.
How can organizations partner with Qubit Pharmaceuticals?
Organizations can pursue joint drug discovery programs, in-licensing or out-licensing opportunities, and joint R&D programs. Interested parties can contact Qubit directly through their website's partnership inquiry form.
